Palisade Bio is developing PALI-2108, a gut-restricted PDE4 inhibitor targeting ulcerative colitis and Crohn’s disease. Phase 1 trials showed favorable safety, target engagement, and early clinical activity, indicating a potentially differentiated mechanism. With $132.6 million in cash, the company is funded through key Phase 2 efficacy results expected in 2027–2028, minimizing near-term dilution risk. If PALI-2108’s efficacy is confirmed in larger trials, it could achieve significant market value similar to other oral ulcerative colitis therapies that have reached multi-billion dollar acquisitions.
Sigenergy, Australia's leading home battery brand, has introduced a $1,000 discount on its new 9kWh SigenStor battery modules. This discount can be stacked with the Federal Government’s Cheaper Home Batteries Program rebate, potentially allowing hous...
The global Edge AI semiconductor market, valued at $25.36 billion in 2025, is projected to grow to $151.30 billion by 2035 with a CAGR of 19.57%. Growth is fueled by increasing use of AI processors in consumer electronics, automotive, healthcare, and...
Global Power Solutions Corp. announced its registration for the Data Centre West 2026 conference in Calgary, focusing on opportunities in digital infrastructure and scalable power solutions. The company praised Meta's historic $13 billion investment ...
21Shares has made three of its crypto exchange-traded products (ETPs) more accessible to retail investors in France through existing brokerage and bank accounts. The ETPs include Bitcoin Core (CBTC) with low fees, Solana Core Staking (CSOL), and XRP ...
Japan Post Insurance and SCOR have signed a memorandum of understanding to transfer underwriting risks of Postal Life Insurance contracts to a reinsurance vehicle managed by SCOR. Japan Post Insurance will invest in this vehicle to ensure its financi...
